ABVX ABIVAX Société Anonyme

ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...

ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...

ABIVAX Société Anonyme (NASDAQ:ABVX) reported first-half 2026 operating cash use of €102.5 million on September 21, up from €66.6 million a year earlier. The roughly 54% increase highlights the growing cost of advancing obefazimod while preparing for potential commercialization. Cash, cash equivalents and short-term investments totaled €402.4 million as of June 30, 2026. A separate […]

Abivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p

ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn fresh attention after expanding its commercial leadership team by adding four senior executives across marketing, patient services, sales and commercial operations, and market access for its lead candidate, obefazimod. See our latest analysis for ABIVAX Société Anonyme. Those commercial hires and the recent R&D collaboration with Valerio Therapeutics come after a period where ABIVAX Société Anonyme’s 1 month share price return of 33.49% contrasts...

Abivax has expanded its Commercial Leadership Team to prepare for potential U.S. commercialization of obefazimod. The company has agreed a binding term sheet for an exclusive worldwide R&D collaboration with Valerio Therapeutics to develop next generation immune mediated inflammatory disease therapies. The moves combine commercial build out with access to RNA technology platforms and new therapeutic candidates. ABIVAX Société Anonyme (ENXTPA:ABVX) is stepping up its U.S. ambitions as it...